SRR8943006
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.380
- TGF_BETA_SIGNALING+0.250
- ADIPOGENESIS+0.240
- PROTEIN_SECRETION+0.230
- HEME_METABOLISM+0.150
- WNT_BETA_CATENIN_SIGNALING+0.150
- FATTY_ACID_METABOLISM+0.100
- PEROXISOME+0.100
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.100
- PANCREAS_BETA_CELLS+0.090
Top 10 suppressed
- E2F_TARGETS-0.640
- G2M_CHECKPOINT-0.550
- IL6_JAK_STAT3_SIGNALING-0.460
- CHOLESTEROL_HOMEOSTASIS-0.430
- INFLAMMATORY_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- INTERFERON_GAMMA_RESPONSE-0.390
- ALLOGRAFT_REJECTION-0.370
- HEDGEHOG_SIGNALING-0.370
- MITOTIC_SPINDLE-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-78-7167-01A-11R-2066-07 | — | cohortA2 | 0.875 |
| 2 | SRR12202449 | — | — | 0.869 |
| 3 | TCGA-78-7156-01A-11R-2039-07 | — | cohortA2 | 0.846 |
| 4 | TCGA-CF-A5U8-01A-11R-A28M-07 | — | — | 0.832 |
| 5 | SRR2016961 | — | — | 0.821 |
| 6 | TCGA-21-1078-01A-01R-0692-07 | — | cohortSQ1 | 0.817 |
| 7 | TCGA-GM-A2DC-01A-11R-A18M-07 | — | B | 0.817 |
| 8 | 1d0437fc-c8ad-47be-822d-b95ad10f0e4a | — | — | 0.809 |
| 9 | SRR1516088 | — | — | 0.807 |
| 10 | SRR12202454 | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.010 | Inavolisib | — uncovered |